Boehringer Ingelheim

March 6, 2017March 6, 2017

Global IPF Survey Finds Two-thirds of Patients Involved in Treatment Decisions

Results from a new global survey of 152 people living with idiopathic pulmonary fibrosis (IPF) showed that while a majority of these patients have been involved in decisions regarding their ... Read more

February 21, 2017February 21, 2017

Boehringer Ingelheim and Weill Cornell Partner to Investigate Ways of Halting COPD Progression

COPD, News

Boehringer Ingelheim and Weill Cornell Medicine are again working together to identify treatment approaches to chronic obstructive pulmonary disease (COPD) that might halt or even reverse lung tissue damage. Their three-year collaboration will build ... Read more

September 19, 2016September 19, 2016

Spiriva Respimat Safely Improves Lung Function in Kids with Asthma, New Study Results Show

Asthma, News

Boehringer Ingelheim recently announced new results showing that Spiriva Respimat (tiotropium bromide) improved lung function in asthmatic children ages 6 to 11. Data also suggested the drug is safe in children ages 6 ... Read more

August 30, 2016August 30, 2016

Clinicians Debate Management, Diagnosis of Respiratory Illnesses in Middle East

Asthma, COPD, Idiopathic Pulmonary Fibrosis, News

Leading medical professionals of European, Middle Eastern and African countries gathered at Boehringer Ingelheim’s second regional respiratory forum, themed “Innovative Solutions to Help Millions,” in Dubai to debate the clinical practices of ... Read more

August 29, 2016August 29, 2016

Boehringer Ingelheim and Duke Research Institute Expand IPF Patient Registry

News

Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute (DCRI) are expanding the Idiopathic Pulmonary Fibrosis PROspective Outcomes Registry (IPF-PRO), which they say will make it the largest IPF patient registry in the country. The ... Read more

August 2, 2016August 2, 2016

Trial Launches to Evaluate Ofev on IPF-Predicting Biomarkers

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim Pharmaceuticals announced the launch of a new clinical trial to investigate the effects of Ofev (nintedanib) on certain blood biomarkers that might help identify fibrosis and loss of lung function ... Read more

June 14, 2016June 14, 2016

Boehringer Ingelheim, Harvard Scientists Partner to Develop Novel Treatments for IPF, Other Fibrotic Diseases

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim and Harvard Stem Cell Institute’s (HSCI) Harvard Fibrosis Network recently announced a new research partnership to find novel treatments for fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF), chronic kidney ... Read more

June 8, 2016June 8, 2016

Three of Four Asthma Patients Report Reduction in Work Productivity

Asthma, News

A new survey shows that three of four people with symptomatic asthma blame the illness for a significant reduction in productivity at work. On average, asthma patients missed up to three hours ... Read more

June 3, 2016June 6, 2016

Boehringer, Inventiva Form $190M IPF Research and Development Pact

Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim and Dijon, France-based Inventiva Pharma, a biopharma specializing in the development of innovative therapies for fibrosis, have announced the establishment of an idiopathic pulmonary fibrosis (IPF) research and development ... Read more

May 18, 2016May 18, 2016

Efficacy and Safety of Ofev (Nintedanib) as IPF Treatment Supported by New Analyses

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim Pharmaceuticals presented 12 idiopathic pulmonary fibrosis (IPF)-related abstracts at the recent American Thoracic Society (ATS) 2016 Annual Conference, including further analyses of its INPULSIS clinical trial program, which added to the ... Read more